The acquisition adds Kezar's pipeline to Aurinia's portfolio, but the CVR structure means future payouts depend on Kezar's clinical milestones. Monitor Kezar's development progress and any CVR-related disclosures for potential upside or impairment.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 11 $15.72entry
- T+1 · 6mo ago +1.72%α +1.85% · $15.99
- T+5 · 6mo ago −0.76%α −0.68% · $15.60
- T+20 · 5mo ago +0.38%α +0.69% · $15.78
- T+60 · 3mo ago −3.37%α −7.76% · $15.19
Price Chart
How similar events traded
Executive Summary
Aurinia Pharmaceuticals completed its acquisition of Kezar Life Sciences via a tender offer and merger. Shareholders received $6.955 per share in cash plus one contingent value right (CVR) per share. The deal closed on May 11, 2026, with 80.24% of Kezar shares tendered, and the remaining shares were acquired in a subsequent merger without a stockholder vote.
Key Facts
- Aurinia completed the acquisition of Kezar Life Sciences for $6.955 per share in cash plus one CVR per share.
- The tender offer expired on May 8, 2026, with 5,927,580 shares (80.24% of outstanding) validly tendered.
- The merger closed on May 11, 2026, under Section 251(h) of the DGCL without a stockholder vote.
- Outstanding in-the-money stock options were cancelled and converted into cash and CVRs; out-of-the-money options were cancelled for no consideration.
- The CVR Agreement was dated May 11, 2026, with Broadridge as Rights Agent and Fortis Advisors as Representative.
Financial Impact
Total cash consideration for the 5,927,580 shares tendered is approximately $41.2 million (5,927,580 × $6.955). Total deal value including remaining shares and option consideration is not disclosed.
Risk Factors
- CVR payouts are contingent on future milestones and may never materialize.
- Integration risks from absorbing Kezar's operations and pipeline.
- Cash outlay for the acquisition may pressure Aurinia's balance sheet.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-020402 |
| Document: 0001140361-26-020402-index-headers.html | 0001140361-26-020402 |
| Document: 0001140361-26-020402-index.html | 0001140361-26-020402 |
| Document: 0001140361-26-020402.txt | 0001140361-26-020402 |
Track record
7 reports on AUPH
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +10.59% at T+60 after the Feb 26, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Mixed 3/10 Entry $15.42 Now $15.48 +0.39% settles Feb 12
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $16.56 Now $15.48 −6.52% settles Feb 1
- Oct 30, 202617d ago 8-K Neutral 5/10 Entry $16.65 Now $15.48 −7.03% settles Jan 28
- Aug 6, 202614w ago 8-K Bullish 6/10 Entry $16.13 to $16.65 Now $15.48 −4.03% ▲ +3.22% +4.89% vs SPY
- Jun 2, 202623w ago Insider Buy Bullish 6/10 Entry $15.67 to $16.48 Now $15.48 −1.21% ▲ +5.14% +2.90% vs SPY
- May 11, 202627w ago 8-K Neutral 5/10 Viewing Entry $15.72 to $15.19 Now $15.48 −1.53% ▼ −3.37% −7.76% vs SPY
- Feb 26, 202637w ago 8-K Bullish 8/10 Entry $13.97 to $15.45 Now $15.48 +10.81% ▲ +10.59% +2.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers